Why Doesn't Imatinib Cure Chronic Myeloid Leukemia?

Overview

Journal Oncologist

Publisher Oxford University Press

Specialty Oncology

Date 2010 Feb 4

PMID 20124443

Citations 9

Authors

Robert L Redner

Affiliations

Soon will be listed here.

Abstract

Imatinib mesylate has transformed the treatment for chronic myeloid leukemia (CML). The vast majority of patients obtain hematologic remission, with a low probability of progression of disease. Yet imatinib rarely cures CML, and current recommendations dictate lifelong treatment with imatinib. In this review we analyze the biology behind the failure of imatinib to fully eradicate CML. We review evidence that indicates that the leukemic stem cell for CML is inherently resistant to imatinib, and that imatinib treatment itself may enhance this resistance.

Citing Articles

I13 overrides resistance mediated by the T315I mutation in chronic myeloid leukemia by direct BCR-ABL inhibition.

Gao C, Zhang L, Xu Y, Ma X, Chen P, Chen Z Front Pharmacol. 2023; 14:1183052.

PMID: 37124196 PMC: 10130674. DOI: 10.3389/fphar.2023.1183052.

Novel Experimental Therapies for Treatment of Pulmonary Arterial Hypertension.

Zolty R J Exp Pharmacol. 2021; 13:817-857.

PMID: 34429666 PMC: 8380049. DOI: 10.2147/JEP.S236743.

A Broad Overview of Signaling in -Negative Classic Myeloproliferative Neoplasms.

Guijarro-Hernandez A, Vizmanos J Cancers (Basel). 2021; 13(5).

PMID: 33652860 PMC: 7956519. DOI: 10.3390/cancers13050984.

The Search for Disease-Modifying Therapies in Pulmonary Hypertension.

Woodcock C, Chan S J Cardiovasc Pharmacol Ther. 2019; 24(4):334-354.

PMID: 30773044 PMC: 6714051. DOI: 10.1177/1074248419829172.

FZD7 regulates BMSCs-mediated protection of CML cells.

Liu N, Zang S, Liu Y, Wang Y, Li W, Liu Q Oncotarget. 2015; 7(5):6175-87.

PMID: 26716419 PMC: 4868748. DOI: 10.18632/oncotarget.6742.

References

Copland M, Jorgensen H, Holyoake T . Evolving molecular therapy for chronic myeloid leukaemia--are we on target?. Hematology. 2005; 10(5):349-59. DOI: 10.1080/10245330500234195. View

Kantarjian H, Cortes J, OBrien S, Luthra R, Giles F, Verstovsek S . Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alpha. Blood. 2004; 104(7):1979-88. DOI: 10.1182/blood-2004-02-0711. View

Oravecz-Wilson K, Philips S, Yilmaz O, Ames H, Li L, Crawford B . Persistence of leukemia-initiating cells in a conditional knockin model of an imatinib-responsive myeloproliferative disorder. Cancer Cell. 2009; 16(2):137-48. PMC: 2763369. DOI: 10.1016/j.ccr.2009.06.007. View

Jagani Z, Song K, Kutok J, Dewar M, Melet A, Santos T . Proteasome inhibition causes regression of leukemia and abrogates BCR-ABL-induced evasion of apoptosis in part through regulation of forkhead tumor suppressors. Cancer Res. 2009; 69(16):6546-55. PMC: 2763358. DOI: 10.1158/0008-5472.CAN-09-0605. View

Jordanides N, Jorgensen H, Holyoake T, Mountford J . Functional ABCG2 is overexpressed on primary CML CD34+ cells and is inhibited by imatinib mesylate. Blood. 2006; 108(4):1370-3. DOI: 10.1182/blood-2006-02-003145. View

Brendel C, Scharenberg C, Dohse M, Robey R, Bates S, Shukla S . Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells. Leukemia. 2007; 21(6):1267-75. DOI: 10.1038/sj.leu.2404638. View

Cortes J, Talpaz M, OBrien S, Jones D, Luthra R, Shan J . Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate. Clin Cancer Res. 2005; 11(9):3425-32. DOI: 10.1158/1078-0432.CCR-04-2139. View

Hughes T, Kaeda J, Branford S, Rudzki Z, Hochhaus A, Hensley M . Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med. 2003; 349(15):1423-32. DOI: 10.1056/NEJMoa030513. View

Mauro M, Druker B, Maziarz R . Divergent clinical outcome in two CML patients who discontinued imatinib therapy after achieving a molecular remission. Leuk Res. 2004; 28 Suppl 1:S71-3. DOI: 10.1016/j.leukres.2003.10.017. View

10.

Dick J, Lapidot T . Biology of normal and acute myeloid leukemia stem cells. Int J Hematol. 2006; 82(5):389-96. DOI: 10.1532/IJH97.05144. View

11.

Rousselot P, Huguet F, Rea D, Legros L, Cayuela J, Maarek O . Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood. 2006; 109(1):58-60. DOI: 10.1182/blood-2006-03-011239. View

12.

Holtz M, Forman S, Bhatia R . Growth factor stimulation reduces residual quiescent chronic myelogenous leukemia progenitors remaining after imatinib treatment. Cancer Res. 2007; 67(3):1113-20. DOI: 10.1158/0008-5472.CAN-06-2014. View

13.

Jorgensen H, Allan E, Graham S, Godden J, Richmond L, Elliott M . Lonafarnib reduces the resistance of primitive quiescent CML cells to imatinib mesylate in vitro. Leukemia. 2005; 19(7):1184-91. DOI: 10.1038/sj.leu.2403785. View

14.

Bruns I, Czibere A, Fischer J, Roels F, Cadeddu R, Buest S . The hematopoietic stem cell in chronic phase CML is characterized by a transcriptional profile resembling normal myeloid progenitor cells and reflecting loss of quiescence. Leukemia. 2009; 23(5):892-9. DOI: 10.1038/leu.2008.392. View

15.

Druker B . Translation of the Philadelphia chromosome into therapy for CML. Blood. 2008; 112(13):4808-17. DOI: 10.1182/blood-2008-07-077958. View

16.

Michor F, Hughes T, Iwasa Y, Branford S, Shah N, Sawyers C . Dynamics of chronic myeloid leukaemia. Nature. 2005; 435(7046):1267-70. DOI: 10.1038/nature03669. View

17.

Rosti G, Martinelli G, Bassi S, Amabile M, Trabacchi E, Giannini B . Molecular response to imatinib in late chronic-phase chronic myeloid leukemia. Blood. 2003; 103(6):2284-90. DOI: 10.1182/blood-2003-07-2575. View

18.

Vicente-Duenas C, Perez-Caro M, Abollo-Jimenez F, Cobaleda C, Sanchez-Garcia I . Stem-cell driven cancer: "hands-off" regulation of cancer development. Cell Cycle. 2009; 8(9):1314-8. DOI: 10.4161/cc.8.9.8217. View

19.

Haeno H, Levine R, Gilliland D, Michor F . A progenitor cell origin of myeloid malignancies. Proc Natl Acad Sci U S A. 2009; 106(39):16616-21. PMC: 2757818. DOI: 10.1073/pnas.0908107106. View

20.

Hope K, Jin L, Dick J . Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity. Nat Immunol. 2004; 5(7):738-43. DOI: 10.1038/ni1080. View